Featured Research

from universities, journals, and other organizations

Research on inflammasomes opens new therapeutic avenues for treatment of rheumatoid arthritis

Date:
July 1, 2014
Source:
VIB - Flanders Interuniversity Institute for Biotechnology
Summary:
Patients with varying severity of rheumatoid arthritis (RA) may have the same painful symptoms, but does this mean that the cause of their illness is the same and that they should all receive the same treatment? Scientists have demonstrated with their research into inflammasomes that RA should be considered as a syndrome rather than a single disease.

Patients with more or less severe forms of rheumatoid arthritis (RA) may have the same painful symptoms, but does this mean that the cause of their illness is the same? And therefore that they should all receive the same treatment? Scientists at VIB and Ghent University have demonstrated with their research into inflammasomes that RA should be considered as a syndrome rather than a single disease.

Related Articles


Mohamed Lamkanfi (VIB/Ghent University): "Rheumatoid arthritis (RA) can be very painful and it is not always easy to find the most suitable medicine. Until recently, RA was considered to be a single disease, but our research suggests that it is more likely to be a syndrome than a single disease. This knowledge could result in a more personalized approach to treatment, with the most suitable medicines selected according to the patient's profile."

Rheumatoid arthritis and inflammasomes Rheumatoid arthritis (RA) is an inflammatory disease that affects the joints and without treatment it evolves into a debilitating and painful condition that can severely affect the patient's quality of life. An estimated 1 to 2 % of the world's population suffers from RA; this equates to approximately 5 million people in Europe.

Inflammasomes are protein complexes that form part of our immune system. Scientists have suspected for some time that inflammasomes play a role in the development and progression of RA. Lieselotte Vande Walle and Mohamed Lamkanfi have been able to demonstrate the role of inflammasomes in RA using a specific mouse model with RA, developed by VIB colleagues Geert van Loo and Rudi Beyaert in Ghent.

They were able to combat the development of RA by blocking inflammasomes. One of the processes accounted for by inflammasomes is the production of interleukin-1, a protein with an important role in inflammatory reactions. Stopping the effects of interleukin-1 resulted in a cure for the mice. In this manner, Vande Walle and Lamkanfi demonstrated that the mouse model is perfectly suitable for studying the correlation between inflammasomes and RA.

A new therapeutic target This first mouse model that places the genetic focus on the inflammasomes also lays the foundations for developing new treatments. Previous research has already demonstrated that other proteins in our immune system -- such as TNF and IL-17 -- could possibly play a role in RA. Medicines have since been developed to combat these proteins and thereby cure RA. These research results demonstrate that a further therapeutic option could be the blocking of the inflammasome (or the resulting IL-1).

Medicine to order The research by VIB scientists also demonstrates that RA is a syndrome rather than a single disease, in other words that similar symptoms can have various different causes. If one knows the cause, one can offer very targeted treatment. In the case of genetic forms of breast, skin and lung cancer it is already possible to predict with great accuracy -- by means of genetic tests -- whether a treatment will work or not. We could evolve towards a more personalized approach for RA too. People with RA may all have the same symptoms, but the underlying genetic causes can differ. And so the future treatment options will differ too. A new challenge for many scientists!


Story Source:

The above story is based on materials provided by VIB - Flanders Interuniversity Institute for Biotechnology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lieselotte Vande Walle, Nina Van Opdenbosch, Peggy Jacques, Amelie Fossoul, Eveline Verheugen, Peter Vogel, Rudi Beyaert, Dirk Elewaut, Thirumala-Devi Kanneganti, Geert van Loo, Mohamed Lamkanfi. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature, 2014; DOI: 10.1038/nature13322

Cite This Page:

VIB - Flanders Interuniversity Institute for Biotechnology. "Research on inflammasomes opens new therapeutic avenues for treatment of rheumatoid arthritis." ScienceDaily. ScienceDaily, 1 July 2014. <www.sciencedaily.com/releases/2014/07/140701085322.htm>.
VIB - Flanders Interuniversity Institute for Biotechnology. (2014, July 1). Research on inflammasomes opens new therapeutic avenues for treatment of rheumatoid arthritis. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2014/07/140701085322.htm
VIB - Flanders Interuniversity Institute for Biotechnology. "Research on inflammasomes opens new therapeutic avenues for treatment of rheumatoid arthritis." ScienceDaily. www.sciencedaily.com/releases/2014/07/140701085322.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins